Alexion Pharmaceuticals (ALXN) PT Raised to $139 at RBC Capital After Revenue Guidance Increase at Analyst Day
Tweet Send to a Friend
RBC Capital analyst Kennen MacKay raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $139.00 (from $136.00) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
